DZ1894A1 - Médicaments à effet anti-hyperglicemique. - Google Patents

Médicaments à effet anti-hyperglicemique.

Info

Publication number
DZ1894A1
DZ1894A1 DZ950067A DZ950067A DZ1894A1 DZ 1894 A1 DZ1894 A1 DZ 1894A1 DZ 950067 A DZ950067 A DZ 950067A DZ 950067 A DZ950067 A DZ 950067A DZ 1894 A1 DZ1894 A1 DZ 1894A1
Authority
DZ
Algeria
Prior art keywords
hyperglicemic
medicines
effect
prepn
antihyperglycaemically
Prior art date
Application number
DZ950067A
Other languages
English (en)
Inventor
Elbert Kann
Dieter Bruckner Rienha Ziegler
Original Assignee
Kali Chemie Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kali Chemie Pharma Gmbh filed Critical Kali Chemie Pharma Gmbh
Application granted granted Critical
Publication of DZ1894A1 publication Critical patent/DZ1894A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Dental Preparations (AREA)
  • Fats And Perfumes (AREA)
DZ950067A 1994-07-01 1995-05-30 Médicaments à effet anti-hyperglicemique. DZ1894A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4423177A DE4423177A1 (de) 1994-07-01 1994-07-01 Antihyperglykämisch wirksame Arzneimittel

Publications (1)

Publication Number Publication Date
DZ1894A1 true DZ1894A1 (fr) 2002-02-17

Family

ID=6522064

Family Applications (1)

Application Number Title Priority Date Filing Date
DZ950067A DZ1894A1 (fr) 1994-07-01 1995-05-30 Médicaments à effet anti-hyperglicemique.

Country Status (23)

Country Link
US (1) US5712283A (fr)
EP (1) EP0689837B1 (fr)
JP (1) JP3841846B2 (fr)
KR (1) KR100366130B1 (fr)
CN (1) CN1092961C (fr)
AT (1) ATE210444T1 (fr)
AU (1) AU691580B2 (fr)
CA (1) CA2152998C (fr)
CZ (1) CZ287563B6 (fr)
DE (2) DE4423177A1 (fr)
DK (1) DK0689837T3 (fr)
DZ (1) DZ1894A1 (fr)
ES (1) ES2167385T3 (fr)
FI (1) FI117374B (fr)
HU (1) HU226946B1 (fr)
IL (1) IL113411A (fr)
NO (1) NO307029B1 (fr)
NZ (1) NZ270990A (fr)
PT (1) PT689837E (fr)
RU (1) RU2145857C1 (fr)
SK (1) SK282227B6 (fr)
UA (1) UA27954C2 (fr)
ZA (1) ZA954691B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2212294A1 (fr) * 1995-02-28 1996-09-06 Beiersdorf-Lilly Gmbh Utilisation de la moxonidine pour le traitement de l'atherosclerose
EP0914128A1 (fr) * 1996-06-06 1999-05-12 Eli Lilly And Company Formulation et methode pour traiter l'insuffisance cardiaque congestive
ZA981029B (en) * 1997-02-11 1999-08-10 Lilly Co Eli Pharmaceutical agents.
DE19722322A1 (de) * 1997-05-28 1998-12-03 Solvay Pharm Gmbh Nephroprotektives Arzneimittel
JP2001520195A (ja) * 1997-10-17 2001-10-30 イーライ・リリー・アンド・カンパニー 医薬の増強
US6897019B1 (en) * 1998-04-17 2005-05-24 Tufts College Methods for treating and preventing insulin resistance and related disorders
WO2000044355A1 (fr) * 1999-01-29 2000-08-03 Eli Lilly And Company Sels de moxonidine
PT1150680E (pt) * 1999-02-01 2005-03-31 Solvay Pharm Gmbh Utilizacao de moxonidima para o tratamento apos enfarte cardiaco
DE19911371A1 (de) 1999-03-15 2000-09-21 Solvay Pharm Gmbh Arzneimittel zur Behandlung von funktionellen Störungen und Erkrankungen der unteren Darmwege, insbesondere von damit einhergehenden abdominalen visceralen Schmerzen
RU2219930C2 (ru) * 2001-09-24 2003-12-27 Государственное образовательное учреждение высшего профессионального образования Санкт-Петербургская государственная медицинская академия им. И.И. Мечникова Способ лечения заболеваний печени
PL372695A1 (en) * 2002-06-19 2005-07-25 Solvay Pharmaceuticals Gmbh Medicament for the treatment of diseases requiring inhibition or a reduction in the activity of ph value-regulating bicarbonate transporter proteins
BRPI0415198A (pt) * 2003-10-10 2006-12-05 Solvay Pharm Gmbh composição farmacêutica compreendendo um agonista seletivo do receptor da imidazolina i1 e um bloqueador do receptor da angiotensina ii
RU2426543C1 (ru) * 2010-05-24 2011-08-20 Учреждение Российской академии медицинских наук Научно-исследовательский институт фармакологии Сибирского отделения РАМН НИИ фармакологии СО РАМН Способ дифференцированного назначения моксонидина у пациентов с артериальной гипертензией на фоне метаболического синдрома
RU2542462C2 (ru) * 2013-06-28 2015-02-20 Андрей Владиславович Струтынский Способ коррекции кризового течения гипертонической болезни и абдоминального ожирения

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4323570A (en) * 1978-11-15 1982-04-06 Beiersdorf Aktiengesellschaft Substituted aminopyrimidines
DE2849537C2 (de) * 1978-11-15 1983-03-17 Beiersdorf Ag, 2000 Hamburg Substituierte 5-(2-Imidazolin-2-yl)-aminopyrimidine, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
FR2669927B1 (fr) * 1990-11-29 1994-04-08 Adir Cie Nouveaux derives de guanidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.

Also Published As

Publication number Publication date
FI953256L (fi) 1996-01-02
HUT72599A (en) 1996-05-28
US5712283A (en) 1998-01-27
ES2167385T3 (es) 2002-05-16
EP0689837B1 (fr) 2001-12-12
IL113411A (en) 1999-07-14
FI117374B (fi) 2006-09-29
JPH0840906A (ja) 1996-02-13
DE59509928D1 (de) 2002-01-24
CZ287563B6 (en) 2000-12-13
CA2152998A1 (fr) 1996-01-02
AU691580B2 (en) 1998-05-21
JP3841846B2 (ja) 2006-11-08
HU226946B1 (en) 2010-03-29
KR960003729A (ko) 1996-02-23
ZA954691B (en) 1996-01-29
CN1092961C (zh) 2002-10-23
SK282227B6 (sk) 2001-12-03
NO952624L (no) 1996-01-02
DE4423177A1 (de) 1996-01-04
FI953256A0 (fi) 1995-06-30
CN1122224A (zh) 1996-05-15
DK0689837T3 (da) 2002-03-11
NZ270990A (en) 1997-06-24
EP0689837A3 (fr) 1996-06-05
HU9501900D0 (en) 1995-08-28
CA2152998C (fr) 2002-09-03
AU1775795A (en) 1996-01-18
CZ139395A3 (en) 1996-01-17
IL113411A0 (en) 1995-07-31
PT689837E (pt) 2002-04-29
NO952624D0 (no) 1995-06-30
ATE210444T1 (de) 2001-12-15
KR100366130B1 (ko) 2003-03-26
EP0689837A2 (fr) 1996-01-03
NO307029B1 (no) 2000-01-31
SK74995A3 (en) 1996-05-08
UA27954C2 (uk) 2000-10-16
RU2145857C1 (ru) 2000-02-27

Similar Documents

Publication Publication Date Title
DZ1894A1 (fr) Médicaments à effet anti-hyperglicemique.
DE59010810D1 (de) Arzneimittel enthaltend als Wirkstoff R-alpha-Liponsäure oder S-alpha-Liponsäure
ES2139638T3 (es) 1,4-piperazinas disustituidas para el tratamiento de las enfermedades del sistema nervioso central y de las enfermedades neuroendocrinas.
ATE87481T1 (de) Orale arzneimittelformen von pimobendan.
DE69231298D1 (de) Substituierte Dibenzoxazepinverbindungen, pharmazeutische Zusammensetzungen und Anwendungsmethoden
ZA874812B (en) Drug
EP0369887A3 (fr) Utilisation de trifluorométhylphényltétrahydropyridines pour la préparation de médicaments destinés à combattre les troubles anxio-dépressifs
NO923199D0 (no) Terapeutiske forbindelser
DE58906387D1 (de) Verwendung von Benzimidazolen zur Herstellung eines Arzneimittels mit antiischämischen Wirkungen am Herzen und dessen Kombinationen mit Beta-Blockern oder Bradycardica.
NO923200D0 (no) Piperidin-derivater
ATE127343T1 (de) Pharmazeutische zubereitung von roxindol oder carmoxirol mit vorgeqüollener stärke.
FI923662A0 (fi) Terapeutiska medel.
CA2038025A1 (fr) Derives de l'alkylenedioxybenzene optiquement actifs et leur utilisation a des fins therapeutiques
EP0471388A3 (fr) Médicament pour le traitement de l'insuffisance cardiaque
GR861646B (en) 4-amino-2-(imidazolidin-2-on-1-yl)-pyrimidino-5-carbonic acid -(n-triphthoro - methyl-phenyl)-amides for antithrombotic protection and treatment use and preparation of antithrombotically active medicines
SE8601963D0 (sv) O-sulfated beta-lactam hydroxamic acids
ATE116296T1 (de) Säureadditionssalze einer optisch aktiven alaninanilidverbindung und diese enthaltende, pharmazeutische zusammensetzungen.
FI884911A0 (fi) Laekemedel, i dessa saosom aktiva aemnen befintliga fosforin innehaollande 2-isoxazoliner och isoxazoler samt foerfarande foer framstaellning av dessa heterocykliska foereningar.
DK0499586T3 (da) Substitueret benzofuranylpiperidin som nootropikum
MX9102181A (es) Iminobenzodiazepina para el tratamiento de desordenes del sueno
JPS6434920A (en) Therapy for mycobacterium abium intracellular complex infection
FI941850A0 (fi) Uusi yhdiste, joka on leustroduksiini H, sen valmistus ja terapeuttinen käyttö
IT1191617B (it) Propionilanilidi farmacologicamente attive